Japan's Tella Collaborates With Korean Venture Firm In Cell Therapies
This article was originally published in PharmAsia News
Executive Summary
Japanese JASDAQ-listed Tella signed a memorandum of understanding with Korean venture firm CreaGene to jointly develop anti-cancer cell therapies in Japan